SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant |X|
Filed by a Party other than the Registrant |_|
Check the appropriate box:
|_| Preliminary Proxy Statement
|_| Confidential, for Use of the Commission Only
(as permitted by Rule 14a-6(e)(2)
|_| Definitive Proxy Statement
|X| Definitive Additional Materials
|_| Soliciting Material Pursuant to ss.240.14a-11(c) or ss.240.14a-12
Aquila Biopharmaceuticals, Inc.
________________________________________________________________________________
(Name of Registrant as Specified In Its Charter)
________________________________________________________________________________
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
|X| No Fee Required
|_| Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
1. Title of each class of securities to which transaction applies:
--------------------------------------------------------------------
2. Aggregate number of securities to which transaction applies:
--------------------------------------------------------------------
3. Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (set forth the amount on which
the filing fee is calculated and state how it was determined):
--------------------------------------------------------------------
4. Proposed maximum aggregate value transaction:
--------------------------------------------------------------------
5. Total fee paid:
--------------------------------------------------------------------
|_| Fee paid previously with preliminary materials.
|_| Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration number, or
the Form or Schedule and the date of its filing.
1. Amount previously paid:
--------------------------------------------------------------------
2. Form, Schedule or Registration Statement No.:
--------------------------------------------------------------------
3. Filing Party:
--------------------------------------------------------------------
4. Date Filed:
--------------------------------------------------------------------
<PAGE>
October 20, 2000
Dear Fellow Stockholder:
We have previously sent to you proxy material for the special meeting of common
stockholders of Aquila Biopharmaceuticals, Inc. to be held on November 15, 2000.
At the meeting, we will ask you to vote on a proposal to adopt a merger
agreement with Antigenics Inc. Your board of directors unanimously recommends
that you vote "FOR" the adoption of the merger agreement.
To approve the merger, a majority of the outstanding shares of Aquila stock must
affirmatively vote for adoption of the merger agreement. If you fail to vote, or
abstain from voting, it will have the same effect as a vote against the merger.
Your vote is very important, no matter how many or how few shares you may own.
If you have not yet voted, please vote TODAY by telephone, by Internet, or by
signing and returning the enclosed voting form in the postage-paid envelope
provided.
Thank you for your support.
Sincerely,
Alison Taunton-Rigby, Ph.D.
President and Chief Executive Officer
================================================================================
IMPORTANT NOTE:
Remember, you may vote by telephone or Internet -- Simply
follow the easy instructions on the enclosed voting form.
If you have any questions, or need assistance in voting your
shares, please call our proxy solicitor:
INNISFREE M&A INCORPORATED
TOLL-FREE at 1-888-750-5834
================================================================================
